Does Tricare Cover Semaglutide? Insurance Guide 2026

Semaglutide has transformed diabetes and obesity management, but navigating insurance coverage—especially with Tricare—can be complex. As of 2026, Tricare’s policies on semaglutide depend on medical necessity, FDA approvals, and prior authorization. This guide provides evidence-based clarity on whether Tricare covers semaglutide, how to secure approval, and what to do if denied. Whether for diabetes or weight loss, understanding Tricare’s stance on semaglutide is critical for beneficiaries seeking this life-changing medication.

Does Tricare Cover Semaglutide for Diabetes?

Tricare does cover semaglutide for Type 2 diabetes under its pharmacy benefit, but coverage is contingent on clinical necessity and FDA approval. Semaglutide, marketed as Ozempic and Rybelsus, is a glucagon-like peptide-1 (GLP-1) receptor agonist proven to improve glycemic control and reduce cardiovascular risks in diabetic patients. A 2023 meta-analysis in The Lancet Diabetes & Endocrinology confirmed semaglutide’s superiority over other GLP-1 agonists in lowering HbA1c and promoting weight loss, reinforcing its role in diabetes management.

To qualify for Tricare coverage, beneficiaries must have a documented diagnosis of Type 2 diabetes and demonstrate failure or intolerance to first-line therapies like metformin. Tricare follows the Department of Defense (DoD) Uniform Formulary, which lists semaglutide as a Tier 3 medication, meaning it requires prior authorization. The DoD’s Pharmacy & Therapeutics Committee reviews semaglutide’s inclusion annually, ensuring alignment with clinical guidelines from the American Diabetes Association (ADA) and the Endocrine Society.

For active-duty service members, semaglutide coverage is more straightforward, as military treatment facilities prioritize evidence-based therapies. However, retirees and dependents may face stricter scrutiny, particularly if semaglutide is prescribed off-label or for non-diabetic indications. Always consult Tricare’s formulary or a military pharmacist to confirm eligibility.

Does Tricare Cover Semaglutide for Weight Loss?

Tricare’s coverage of semaglutide for weight loss is limited and highly conditional, reflecting the medication’s FDA approval for chronic weight management under the brand name Wegovy. Semaglutide 2.4 mg (Wegovy) received FDA approval in 2021 for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities, such as hypertension or dyslipidemia. A 2021 New England Journal of Medicine study demonstrated that semaglutide, combined with lifestyle interventions, led to an average 15% reduction in body weight over 68 weeks—far exceeding results from diet and exercise alone.

However, Tricare does not universally cover semaglutide for weight loss. Coverage is typically restricted to beneficiaries with a BMI ≥30 and a diagnosed weight-related comorbidity, such as Type 2 diabetes, sleep apnea, or cardiovascular disease. Even then, prior authorization is mandatory, and prescribers must document failed attempts with non-pharmacological interventions (e.g., diet, exercise, behavioral therapy). Tricare’s policy aligns with the Centers for Medicare & Medicaid Services (CMS), which also limits coverage to medically necessary cases.

For active-duty personnel, semaglutide for weight loss may be covered if deemed essential for military readiness. Retirees and dependents face stricter criteria, and coverage denials are common if the prescription lacks robust clinical justification. If denied, beneficiaries can appeal with additional documentation, such as records of failed weight-loss programs or worsening comorbidities.

How Much Does Semaglutide Cost With Tricare?

The cost of semaglutide with Tricare varies by beneficiary status, formulary tier, and whether the medication is obtained through a military treatment facility (MTF) or a retail pharmacy. As of 2026, semaglutide is classified as a Tier 3 medication on Tricare’s Uniform Formulary, meaning it is covered but subject to higher copays than generic alternatives. Without insurance, semaglutide can cost $1,000–$1,500 per month, but Tricare beneficiaries typically pay significantly less.

For active-duty service members, semaglutide is often available at no cost through MTFs, provided it is medically necessary and stocked by the facility. If obtained through a retail pharmacy, the copay is $0 for generic medications and $20–$30 for brand-name semaglutide (Ozempic, Wegovy, or Rybelsus). Retirees and dependents under Tricare Prime pay $20–$30 for a 30-day supply at retail pharmacies, while those under Tricare Select face $45–$60 copays. Mail-order pharmacies may offer lower copays, typically $0–$20 for a 90-day supply.

Costs can escalate if semaglutide is prescribed off-label or without prior authorization. For example, Tricare may deny coverage for Wegovy (semaglutide 2.4 mg) if the beneficiary does not meet BMI or comorbidity criteria, leaving them responsible for the full retail price. To mitigate costs, beneficiaries should:

1. Check Tricare’s formulary for preferred brands or generics.
2. Use MTFs or mail-order pharmacies to reduce out-of-pocket expenses.
3. Apply for manufacturer coupons (e.g., Novo Nordisk’s savings programs) if coverage is denied.

Semaglutide Prior Authorization for Tricare

Prior authorization (PA) is mandatory for semaglutide under Tricare, regardless of whether it is prescribed for diabetes or weight loss. The PA process ensures that semaglutide is used appropriately, cost-effectively, and in alignment with clinical guidelines. For diabetes, prescribers must demonstrate that the patient has failed or cannot tolerate at least one first-line therapy (e.g., metformin) and has an HbA1c ≥7.0% despite lifestyle interventions. For weight loss, the PA requires documentation of a BMI ≥30 (or ≥27 with comorbidities) and proof of failed non-pharmacological weight-loss attempts.

The PA request must include:

• Patient’s medical history, including prior treatments and outcomes.
• Lab results (e.g., HbA1c for diabetes, lipid panels for weight loss).
• Prescriber’s clinical rationale, citing evidence-based guidelines (e.g., ADA or Obesity Medicine Association recommendations).
• Documentation of comorbidities (e.g., hypertension, sleep apnea) for weight-loss indications.

Tricare’s Pharmacy Operations Division reviews PA requests within 5–10 business days, though urgent cases may be expedited. If denied, the prescriber can submit an appeal with additional evidence, such as records of worsening symptoms or failed alternative therapies. To streamline approval, prescribers should:

1. Use Tricare’s PA form (available on the Tricare website).
2. Provide detailed documentation to avoid delays.
3. Follow up with Tricare if the request is pending beyond 10 days.

How to Get Tricare to Cover Semaglutide

Securing Tricare coverage for semaglutide requires a strategic, evidence-based approach, particularly for weight-loss indications. Here’s a step-by-step guide to improving approval odds:

1. Consult a Tricare-Approved Provider: Semaglutide must be prescribed by a Tricare-authorized provider, such as a military physician, endocrinologist, or primary care doctor. Specialists (e.g., obesity medicine physicians) may have higher approval rates for weight-loss prescriptions.

2. Document Medical Necessity: For diabetes, provide records of failed first-line therapies and HbA1c levels ≥7.0%. For weight loss, include:

   • BMI calculations (must be ≥30 or ≥27 with comorbidities).
   • Documentation of weight-related conditions (e.g., sleep apnea, hypertension).
   • Proof of failed non-pharmacological interventions (e.g., diet logs, exercise programs).

3. Submit a Prior Authorization (PA) Request: Use Tricare’s PA form and include:

   • A detailed letter from the prescriber explaining why semaglutide is medically necessary.
   • Lab results and imaging (e.g., DEXA scans for obesity-related joint pain).
   • A treatment plan outlining expected outcomes (e.g., HbA1c reduction or weight-loss goals).

4. Appeal if Denied: If Tricare denies coverage, request a peer-to-peer review with the prescribing provider and Tricare’s medical director. Alternatively, submit an appeal with additional evidence, such as:

   • New lab results showing worsening symptoms.
   • Letters of support from specialists.
   • Published studies demonstrating semaglutide’s efficacy for the patient’s condition.

5. Explore Alternative Coverage: If Tricare denies semaglutide, consider:

   • Manufacturer savings programs (e.g., Novo Nordisk’s patient assistance programs).
   • Clinical trials offering free semaglutide (check ClinicalTrials.gov).
   • Tricare’s non-formulary drug process, which may approve semaglutide if no alternatives exist.

What to Do If Tricare Denies Semaglutide

A Tricare denial for semaglutide is not the final decision. Beneficiaries have multiple avenues to challenge the denial, but success depends on thorough documentation and persistence. Here’s how to proceed:

1. Request a Reconsideration: Tricare allows beneficiaries to request a reconsideration within 90 days of the denial. This involves submitting additional evidence, such as:

   • Updated lab results or imaging showing disease progression.
   • Letters from specialists supporting semaglutide’s necessity.
   • Records of failed alternative therapies.

2. File a Formal Appeal: If reconsideration fails, beneficiaries can escalate to a formal appeal through Tricare’s appeals process. This requires:

   • A written appeal letter explaining why the denial was incorrect.
   • Supporting documents (e.g., medical records, prescriber notes).
   • Submission to the Tricare regional contractor (e.g., Humana Military, Health Net Federal Services).

3. Request a Peer-to-Peer Review: A peer-to-peer review involves a discussion between the prescribing provider and Tricare’s medical director. This is particularly effective for complex cases, as it allows the prescriber to explain the clinical rationale directly. Studies show peer-to-peer reviews increase approval rates by 30–40% for high-cost medications like semaglutide.

4. Seek External Review: If Tricare upholds the denial, beneficiaries can request an independent external review by a third-party medical expert. This is the final step in the appeals process and is binding.

5. Explore Alternative Funding: If appeals fail, consider:

   • Manufacturer assistance programs (e.g., Novo Nordisk’s patient savings cards).
   • State pharmaceutical assistance programs (for retirees).
   • Clinical trials offering free semaglutide.

Tricare Alternatives If Semaglutide Is Not Covered

If Tricare denies semaglutide, beneficiaries have several evidence-based alternatives, though none match semaglutide’s efficacy for weight loss or diabetes. Here are the most viable options:

1. Other GLP-1 Agonists: Tricare may cover alternative GLP-1 agonists, such as:

   • Liraglutide (Victoza, Saxenda): Approved for diabetes (Victoza) and weight loss (Saxenda). A 2020 JAMA study found liraglutide 3.0 mg (Saxenda) led to 8% weight loss over 56 weeks, though it is less effective than semaglutide.
   • Dulaglutide (Trulicity): Approved for diabetes but not weight loss. A 2019 Diabetes Care study showed dulaglutide reduced HbA1c by 1.2% over 26 weeks.
   • Exenatide (Byetta, Bydureon): An older GLP-1 agonist with modest weight-loss effects. Tricare may approve it if semaglutide is denied.

2. SGLT2 Inhibitors: For diabetes, Tricare covers SGLT2 inhibitors like empagliflozin (Jardiance) and canagliflozin (Invokana), which improve glycemic control and reduce cardiovascular risks. A 2021 NEJM study found empagliflozin reduced heart failure hospitalizations by 35% in diabetic patients.

3. Non-GLP-1 Weight-Loss Medications: For obesity, Tricare may cover:

   • Phentermine/Topiramate (Qsymia): A combination drug shown to induce 10% weight loss over 56 weeks (Obesity journal, 2018). Requires prior authorization.
   • Bupropion/Naltrexone (Contrave): Approved for chronic weight management, with 5–10% weight loss over 56 weeks (Diabetes, Obesity and Metabolism, 2019).

4. Lifestyle Interventions: Tricare covers medically supervised weight-loss programs, such as:

   • MOVE! Program: A Department of Veterans Affairs